What's in Dong-A ST Co., Ltd.'s pipeline?

Dong-A ST Co., Ltd. has 84 drugs in our index: 19 marketed, 0 filed, 15 in Phase 3, 6 in Phase 2, 44 in Phase 1.

Which companies overlap with Dong-A ST Co., Ltd.'s portfolio?

Top competitors by shared drug class: AstraZeneca, Hanmi Pharmaceutical Company Limited, Sanofi, Eurofarma Laboratorios S.A., Daewoong Pharmaceutical Co. LTD..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dong-a-st-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Dong-A ST Co., Ltd. — Portfolio Competitive Intelligence Brief

Dong-A ST Co., Ltd. pipeline: 19 marketed, 0 filed, 15 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

19 marketed 0 filed 15 Phase 3 6 Phase 2 44 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Placebo of Acetyl-L-Carnitine	Placebo of Acetyl-L-Carnitine	marketed
Stillen Tab.	Stillen Tab.	marketed	Digestive enzyme preparation		Gastroenterology
DA-5218-C	DA-5218-C	marketed			Other
Pantoline®	Pantoline®	marketed
DA-5218	DA-5218	marketed			Other
CELBESTA®	CELBESTA®	marketed			Other
DA-2803	DA-2803	marketed			Other
DA-2803-R	DA-2803-R	marketed			Other
Rosuvastatin(Cresnon®)	Rosuvastatin(Cresnon®)	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	Cardiovascular
DA-2811	DA-2811	marketed			Other
Stillen	Stillen	marketed			Other
Baraclude Tab.®	Baraclude Tab.®	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase	Virology / Hepatology

Therapeutic area mix

Other · 7
Gastroenterology · 4
Endocrinology · 3
Oncology, Hematology, Immunology · 2
Diabetes · 1
Hematology/Oncology · 1
Neurology, Geriatrics, Metabolic disorders · 1
Neurology/Psychiatry · 1
Neurology; Psychiatry · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 4 shared drug classes
Hanmi Pharmaceutical Company Limited · 3 shared drug classes
Sanofi · 3 shared drug classes
Eurofarma Laboratorios S.A. · 2 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 2 shared drug classes
Handok Inc. · 2 shared drug classes
Chong Kun Dang Pharmaceutical · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Dong-A ST Co., Ltd.:

Cite this brief

Drug Landscape (2026). Dong-A ST Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dong-a-st-co-ltd. Accessed 2026-05-16.